For biopharmaceutical companies, gene therapies are an economic challenge. They are expensive to make yet the diseases the treat are rare, so manufacturers tend to charge a lot for them to generate ...

Zhejiang Provincial Key Laboratory of Vector Biology and Pathogen Control, Huzhou University has the following research output in the current window (1 February 2025 - 31 January 2026) of the Nature ...

The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...